Published 20 days ago • loading... • Updated 16 days ago
Bayer to Invest $2.2 Billion for Manufacturing Site in New Albany
The plant will create 600 permanent jobs and 1,500 construction jobs as Bayer expands U.S. drug manufacturing.
On Friday, Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, serving as a central element of its long-term U.S. expansion strategy.
New Albany Mayor Sloan Spalding said the facility joins a life sciences cluster including Amgen and Pharmavite, leveraging statewide momentum and the Ohio Life Science Training Center to prepare the workforce.
Ohio Governor Mike DeWine said the project will create 600 high-paying jobs averaging "well over $100,000," alongside roughly 1,500 temporary construction positions on 200 acres.
Jeffrey Kessler, Under Secretary at the U.S. Department of Commerce Bureau of Industry and Security, said the announcement reflects President Trump's economic policies strengthening the United States, while Senator Jon Husted noted it reduces China dependence.
Sebastian Guth, Bayer's chief operating officer for pharmaceuticals, stated the site will become operational in 2031, with finished drug product manufacturing following in 2034, supporting the company's goal to double United States sales by decade's end.